Month: September 2026

Patented technology combines sustainability and performance, supporting next-generation formulations

WILMINGTON, Del., Sept. 22, 2026 (GLOBE NEWSWIRE) — Continuing to scale its Transformed Vegetable Oils (TVO™) technology platform, Ashland Inc. (NYSE: ASH), today announced the global launch of agrimer™ eco-disperse OD TVO™ polymeric dispersant, a patented, nature-based dispersant developed for non-aqueous crop protection formulations. The introduction represents the latest commercial innovation from the TVO™ platform.

Agrimer™ eco-disperse OD was engineered so agrochemical formulators could address the growing industry challenge of delivering high-performance formulations while advancing sustainability goals and meeting increasingly complex regulatory expectations. The new polymeric dispersant enables effective stabilization and uniform dispersion of water-insoluble active ingredients, helping improve formulation performance, stability and application efficiency. The technology offers nature-based, inherently biodegradable and microplastic-free attributes that support the transition toward more environmentally responsible crop protection products.

Derived from transformed vegetable oil, agrimer™ eco-disperse OD helps improve dispersion stability, enhance leaf adhesion, coverage and rain fastness. The technology reduces common formulation challenges such as active ingredient settling and nozzle clogging, helping customers improve product consistency and field performance. Its broad formulation compatibility, ease of use and competitive cost-in-use profile provide additional flexibility for formulators developing suspension concentrates and other non-aqueous formulations.

“Ashland is again converting sustainable science into differentiated commercial solutions that create value for our customers,” said Alessandra Faccin, senior vice president and general manager, Life Sciences, Ashland. “Agrimer™ eco-disperse OD expands our TVO™ platform with a patented technology that helps formulators achieve both sustainability and performance objectives. It reflects the type of innovation that strengthens our portfolio, supports profitable growth and advances our commitment to solving complex formulation challenges.”

Jean J. Gulka, global business director, Life Sciences, Ashland, added, “The launch of agrimer™ eco-disperse OD represents more than a new product introduction. It reinforces the scalability and versatility of our innovative TVO™ technology platform and validates our strategy of investing in differentiated technologies that can address global sustainability trends while delivering tangible customer value. We continue to advance additional opportunities within the platform and view TVO™ as an important engine for future innovation and growth.”

The commercialization of agrimer™ eco-disperse OD supports the Ashland strategy to Innovate and strengthen long-term value creation through innovation-led growth. Samples and commercial quantities are available globally. For more information or to request a sample, interested parties should contact their local Ashland representative or visit ashland.com/agrimer-eco-disperse-od

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as “anticipates,” “believes,” “expects,” “estimates,” “is likely,” “predicts,” “projects,” “forecasts,” “objectives,” “may,” “will,” “should,” “plans” and “intends” and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its Annual Report to Stockholders, quarterly reports and other filings with the Securities and Exchange Commission (“SEC”), news releases and other written and oral communications. These forward-looking statements are based on Ashland’s expectations and assumptions, as of the date such statements are made, regarding Ashland’s future operating performance and financial condition, its strategy as well as the economy and other future events or circumstances.

The risks and uncertainties we face which may cause our actual results to differ materially from the results expressed, projected, or implied in these forward-looking statements include, but are not limited to: Ashland’s aggressive growth goals and the extent to which such goals may be impacted by a failure to optimize our tangible and intangible assets, a failure to identify and integrate acquisition targets, any unexpected costs and liabilities associated with such acquisitions, and goodwill impairment; business disruptions stemming from natural, operational, and other catastrophic events, including disruptions to supply and logistics functions, manufacturing delays, and information technology system and network failures; climate change and related resource impacts; changes in consumer preferences and a reduction in demand for Ashland’s products; risks inherent in operating a global business, including tariffs and other trade policies, geopolitical instability and armed conflict, and challenges associated with hiring and managing a diverse workforce across countries with differing laws, regulations, and cultural practices; economic downturns and disruptions in the financial markets; Ashland’s substantial indebtedness, including the possibility that such indebtedness and related restrictive covenants may adversely affect our future cash flows, limit our ability to repay debt and obtain future financing, place Ashland at a competitive disadvantage, and make us more vulnerable to interest rate increases; our ability to develop and market new products and remain competitive in the markets in which we operate; our ability to pass increases in the costs of energy and raw materials to customers and to fulfill our contractual requirements with customers and vendors; downward pressures on prices and margins; the ability to attract and retain key employees and to provide for effective succession planning; cybersecurity risks, including disruptions to or failures in Ashland’s information technology systems and networks, malicious cyberattacks, and the inadvertent or accidental disclosure or loss of proprietary or sensitive information; Ashland’s ability to effectively protect and enforce its intellectual property rights; exposure to products liability claims; risks related to compliance with environmental, health, and safety regulations, including the potential for costly litigation, remediation, and settlement actions; exposure to pending and threatened asbestos-related litigation; changes in the legal and regulatory landscapes in which we operate; and changes in taxation or adverse tax rulings. These risks and uncertainties also include, but are not limited to, the risk factors set forth in Item 1A. “Risk Factors” of Ashland’s most recent Form 10-K, and in our other periodic reports filed with the SEC. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update publicly any forward-looking statements made in this presentation whether as a result of new information, future events or otherwise. Information on Ashland’s website is not incorporated into or a part of this presentation.

About Ashland
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. Approximately 2,900 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more.

^™ Trademark, Ashland or its subsidiaries, registered in various countries.

FOR FURTHER INFORMATION:

Investor Relations:	Media Relations:
Sandy Klugman	Carolmarie C. Brown
+1 (302) 594-7777	+1 (302) 995-3158
sandy.klugman@ashland.com	ccbrown@ashland.com

Attachments

• Ashland agrimer™ eco-disperse OD polymeric dispersant
• Press_Release_Global_Agrimer_EcoDisperseOD_Launch_FNL_20260922

Autonomous vehicle and ADAS teams using RTMaps will get two compression modes to apply across their pipeline – lossless and content-adaptive.

Join the demonstration at AutoSens Europe in Barcelona, September 22–24, stand 131; and at dSPACE User Conference, September 23 in Santa Clara, California

Herzliya, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) — Beamr Imaging Ltd. (Nasdaq: BMR), a leader in video optimization technology and solutions, and Intempora, a dSPACE company and pioneer in advanced software solutions for autonomous driving, today announced that the companies will demonstrate Beamr’s ML-Safe lossless compression for RTMaps – reducing video data at the point of capture in the test vehicle, in real time, with zero data loss.

The demonstration will be presented at AutoSens Europe, September 22–24 (stand 131), and at the dSPACE User Conference on September 23.

Autonomous vehicle (AV) teams produce massive video datasets. That volume strains every stage of development. It starts at capture in the test vehicle’s data logger, with recordings of tens of terabytes in one shift; grows as data moves to the cloud and data center; and grows again with simulation and training, where teams add synthetic data to what they recorded.

Beamr demonstrates lossless compression for 12-bit Bayer – the test vehicle camera’s raw output. Until now, the encoder in the test vehicle did not accept the 12-bit Bayer format, leaving teams to store it as heavy raw files or discard data they may later need. Beamr’s lossless video data compression runs in real time on the GPU already in the test vehicle’s data logger. Initial Beamr testing showed a 47% reduction on recordings from eight 8-megapixel cameras, nearly doubling how much each vehicle can capture – and smaller files move off the vehicle faster, shortening the time it takes to get recordings to the cloud.

ML-Safe lossless compression joins Beamr’s content-adaptive compression, giving RTMaps users two modes to apply across their pipeline. Content-adaptive compression reduces video data load by up to 50% while preserving ML model accuracy, capture more in the vehicle, and move it faster and at lower cost. RTMaps (Real-Time Multisensor Applications) is a modular development and execution middleware, designed to acquire, synchronize, process, record and replay heterogeneous data streams in real-time.

“The volume of sensor and video data our users move through RTMaps, and then store and manage in IVS (Intempora Validation Suite), keeps growing. Coping with this volume is one of the hardest parts of AV development,” said Nicolas Du Lac, CEO of Intempora. “Compression is essential to keep that data workable, and together with Beamr we are demonstrating it in two modes – lossy when a smaller file with preserved ML accuracy aligns with their needs, and lossless when the data has to stay bit-exact.”

“The volume of high-resolution camera data is one of the biggest challenges our customers face in data logging and data-driven development,” said Peter Ngure, Product Manager at dSPACE. “Efficient compression at the point of capture, without compromising data integrity, is an important building block. We welcome Intempora’s collaboration with technology partners like Beamr, giving RTMaps users more options to manage their data across the toolchain.”

“AV and ADAS teams see value with compression that matches what each development stage needs. Beamr’s ML-Safe solution lets them make this decision with confidence,” said Haggai Barel, Beamr COO. “Teams can already apply lossy content-adaptive compression that reduces data held in the cloud and the datasets that feed simulation and training; and now we are demonstrating lossless compression that keeps data bit-exact where it is captured in the data logger.”

Test ML-Safe compression on your own video data or join us at AutoSens Europe in Barcelona, September 22–24 (stand 131), and at the dSPACE User Conference, West Coast in Santa Clara, California, September 23. Visit beamr.com/lossless

About Beamr

Beamr (Nasdaq: BMR) is a world leader in content-adaptive video compression, trusted by top media companies including Netflix and Paramount. Beamr’s perceptual optimization technology (CABR) is backed by 53 patents and a winner of Emmy® Award for Technology and Engineering. The innovative technology reduces video file sizes by up to 50% while preserving quality and enabling AI-powered enhancements.

Beamr powers efficient video workflows across high-growth markets, such as media and entertainment, user-generated content, machine learning, and autonomous vehicles. Its flexible deployment options include on-premises, private or public cloud, with convenient availability for Amazon Web Services (AWS) and Oracle Cloud Infrastructure (OCI) customers.

For more details, please visit www.beamr.com or the investors’ website www.investors.beamr.com and follow us on Linkedin and X.

About Intempora

Founded in 2000, Intempora is a leading software company based in Paris and a pioneer in providing advanced and innovative software tools for developers of robotics, autonomous vehicles and complex real-time systems for over 25 years. Intempora works closely with OEMs and Tier1 all over the world to fit the expectations of the automotive industry. Since 2020, Intempora is a subsidiary company of the dSPACE group. Together we provide a seamless end-to-end development & testing toolchain for autonomous systems. For more information, visit https://intempora.com and follow us on LinkedIn and Youtube.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements in this communication may include, among other things, statements about Beamr’s strategic and business plans, technology, relationships, objectives and expectations for its business, the impact of trends on and interest in its business, intellectual property or product and its future results, operations and financial performance and condition, including statements relating to Beamr’s plans to demonstrate and expand its lossless and content-adaptive compression technologies; the expected availability, integration, performance and benefits of such technologies within RTMaps and autonomous vehicle and ADAS workflows; the ability of such technologies to reduce data volumes, increase effective storage capacity, accelerate data transfers or lower costs; Beamr’s relationships with Intempora, dSPACE and other technology partners; and Beamr’s ability to expand into new markets and convert its strategy and technological capabilities into commercial opportunities. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on February 26, 2026 and in subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of the date hereof and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:

investorrelations@beamr.com

Under Tilray ownership, BrewDog is back on the front foot — with fresh investment, renewed energy and award-winning beers driving the next chapter for one of the UK and Europe’s biggest craft beer brands.

ELLON, Scotland and LONDON, Sept. 22, 2026 (GLOBE NEWSWIRE) — BrewDog, by Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), is launching a major multi-platform marketing campaign to make one message unmistakable: BrewDog is entering a new era under Tilray ownership, with fresh investment, renewed energy and strong backing behind its beers, bars, people and next chapter of growth.

Irwin D. Simon, Chairman and Chief Executive Officer, Tilray Brands, comments: “This is BrewDog’s first major campaign in a long time, and it is only the beginning. Since acquiring BrewDog, Tilray has moved quickly to put real capital, focus and operating discipline behind the business, including nearly £50 million of investment across operations, working capital, people and the platform needed to support growth. BrewDog is one of the biggest and most recognised beer brands in the UK and across Europe, and we see tremendous opportunity to re-energise it, strengthen its connection with consumers, and build it into an even bigger global business. We are proud to keep brewing BrewDog beer in Ellon, proud to honour its Scottish brewing heritage and fully committed to backing the people, beers, bars, and brewing excellence that make BrewDog such a great beer brand. This campaign is a clear signal of our commitment to the brand, and it is one of many investments we intend to make as we drive BrewDog’s next chapter of growth.”

The campaign will bring that message to market through major out-of-home and above-the-line activity across high-impact consumer, customer, and trade touchpoints. Launching on 21 September, it includes large-format outdoor advertising, digital screens in high-traffic areas and a letter from Tilray, BrewDog’s new owner, in 70,000 print copies of City AM. The City AM letter outlines Tilray’s commitment to BrewDog’s future, including renewed investment in the brand, its people, bars, and brewing heritage.

The creative carries the stand-out lines BrewDog fans and customers expect from the brand, including ‘No More Cunning Stunts. Just Great Beer’ alongside Punk IPA, ‘We’ve Flipped the Bird’ alongside Wingman and ‘A Little Less Allegation’ alongside Elvis Juice. Together, the work draws a confident line under the past while keeping BrewDog’s bold, irreverent personality front and centre.

Stuart Harrison, Chief Growth Officer, BrewDog, comments: “For our customers and trade partners, this campaign is just the beginning — and a clear way to show that BrewDog is entering a new era. Under Tilray ownership, we are investing behind the brand, backing our retail, wholesale and on-trade partners, and giving them the tools, offers and visibility to drive footfall, rate of sale and profitable growth. At the centre of that growth is great beer quality — the beers consumers love and the consistency, credibility, and performance our partners expect from BrewDog. We have the scale, recognition, and portfolio to win with consumers and deliver for customers, and we could not be more excited to work with our partners to capture the opportunity ahead.”

John Beasley, Chief Marketing Officer, BrewDog, comments: “BrewDog has always been at its best when it brings energy, attitude, and ambition to the beer category. Under New Ownership is more than a campaign; it is a statement that BrewDog is back with focus, investment, and the creative firepower to reignite momentum. We are here to support our partners, excite customers and remind the market why BrewDog remains one of the UK and Europe’s greatest beer brands.”

The campaign follows strong momentum across BrewDog’s beer portfolio, drinks platform and innovation pipeline. BrewDog recently swept up at the 2026 World Beer Awards, with Hazy Jane, Wingman and Mackie’s Two Scoops earning Gold and Scotland Country Winner awards, while Punk IPA, Lost Lager, Black Heart, and Mello were recognised among the World’s Best Beers.

To support the campaign, BrewDog will offer high-impact promotions and activations across supermarkets, on-trade, convenience, BrewDog bars and online. In grocery, BrewDog will offer £3 four-packs of Punk IPA direct to consumers, backed by high-impact in-store media, digital screens, social activity, and fixture messaging designed to drive visibility, footfall, and rate of sale. The discounted packs will also be available on BrewDog.com for a limited time.

To help pubs and bars bring that momentum to customers, BrewDog is giving new and existing on-trade customers the chance to win one of up to 1,000 free kegs of Wingman, session IPA. Promoted through trade press, route-to-market customers and the field sales team, operators simply register their interest before 12^th October for the chance to win. Full terms and conditions apply.

In October, convenience retailers will be able to buy cases of Punk IPA and Hazy Jane at strong promotional pricing in participating wholesalers, giving them a timely reason to stock BrewDog’s leading beers and pass the saving on to shoppers. High-impact depot and in-store visibility will aim to drive distribution and rate of sale.

Across BrewDog’s UK and Ireland bars, the campaign will bring the ‘Under New Ownership’ message to life through high-impact customer touchpoints from the moment guests walk through the door. Customers will also be invited to raise a glass to BrewDog’s next chapter with a ‘Pint on the New Owner’ available through BrewDog Treats, giving fans and supporters a reason to come in, celebrate the brand’s future and be part of what comes next.

Since acquiring BrewDog, Tilray has invested £50 million to stabilise business operations and has reopened 16 BrewDog bars, including an industry-first community bar in Inverurie, Scotland. BrewDog has also strengthened its growth platform through new partnerships and high-profile brand moments, including a partnership with Underbelly, a five-year official beer partnership with Leicester Tigers, the £1 million World Cup bar tab and Park IPA, a summer out-of-home campaign with Deliveroo that put 20,000 cold cans of Punk IPA into consumers’ hands. Tilray has also expanded BrewDog’s platform beyond its core portfolio. Earlier this year, Tilray, the fourth largest craft brewer in the U.S., introduced 24 Tilray-owned American craft beers into BrewDog bars, including SweetWater, Montauk, 10 Barrel, Shock Top, Alpine, Green Flash and Blue Point, expanding choice for UK consumers and showcasing BrewDog’s bar platform. That platform is also supporting new formats and occasions, including the UK launch of Hi*Ball Energy Drink and BrewDog’s Liquid Visions, a premium craft beer series featuring new hop varieties, fresh beer styles, and creative collaborations. Hi*Ball is also now the official energy drink partner of Wolverhampton Wanders Football Club.

Across supermarkets, pubs, bars and BrewDog’s UK and Ireland venues, the ‘Under New Ownership’ campaign gives consumers, customers and trade partners a clear reason to get behind BrewDog’s next chapter — with great beer, strong promotions and the energy of a brand moving forward with renewed focus, confidence and momentum.

About BrewDog  
BrewDog has always had one mission: to make people as passionate about great beer as we are.

From iconic classics like Punk IPA, to crowd-pleasers like Lost Lager and Wingman, to boundary-pushing innovations like NanoDog, BrewDog has been brewing bold, distinctive beers since 2007.

Born in Scotland and built by a passionate community of beer lovers, BrewDog has grown into one of the world’s most recognisable craft beer brands, with a global presence spanning breweries, bars, and distribution across multiple international markets. BrewDog’s future continues to be shaped by the three things that matter most: People, Planet and Beer.

For more information, visit www.brewdog.com or follow @BrewDog on social media.  

About Tilray Brands 
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages. 

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms. 

Forward-Looking Statements
 Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.  

Tilray Brands Contacts:
Media 
news@tilray.com

Investor Relations 
investors@tilray.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/b7233ed7-0464-41c6-b5da-ec280f18991e

https://www.globenewswire.com/NewsRoom/AttachmentNg/88c0d85e-d226-4861-a299-6dc43bb7a052

https://www.globenewswire.com/NewsRoom/AttachmentNg/19707b60-6741-43b3-8385-01cd404b7423

https://www.globenewswire.com/NewsRoom/AttachmentNg/e4b7bf8f-a5bb-4236-b8ea-9935fb1f28cb

https://www.globenewswire.com/NewsRoom/AttachmentNg/1fc9521a-fd4e-4b7c-8328-71ee0e1d68ba

https://www.globenewswire.com/NewsRoom/AttachmentNg/d73744b8-6f79-4c7b-aab1-9941f019142e

• Deployment strengthens Plug’s growing presence across hydrogen production, refueling and industrial decarbonization projects in New Zealand and Australia
• 1 MW GenEco electrolyzer will produce hydrogen for HWR Hydrogen’s Invercargill refueling station and dual-fuel heavy transport fleet
• From distributed hydrogen production to large-scale industrial projects, Plug technology is supporting a growing range of hydrogen applications across the region

SLINGERLANDS, N.Y., Sept. 22, 2026 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced the shipment of a 1 MW GenEco™ PEM electrolyzer to HWR Hydrogen, a division of H.W. Richardson Group Limited, expanding Plug’s GenEco footprint across New Zealand and Australia.

The unit will be installed at HWR Hydrogen’s refueling station in Invercargill, New Zealand, where it will produce hydrogen to support HWR’s fleet of dual-fuel hydrogen-diesel heavy trucks.

The project represents another step in the development of New Zealand’s emerging hydrogen ecosystem, where locally produced hydrogen is increasingly being deployed to address emissions from heavy transport and other hard-to-decarbonize applications. It also builds on Plug’s existing presence in the country, including deployed electrolyzer technology supporting Hiringa Energy’s green hydrogen refueling network.

Across New Zealand and Australia, hydrogen projects are moving into real-world deployment across transportation, refueling and industrial applications, ranging from distributed production serving local demand to major industrial projects requiring hundreds of megawatts of electrolyzer capacity.

“What’s important about this project isn’t simply the size of the electrolyzer. It’s what it represents,” said José Luis Crespo, CEO of Plug. “Plug is building a strong presence alongside this emerging market, with the technology and experience to support projects at every scale. As hydrogen adoption grows across New Zealand and Australia, we’re positioned to grow with it.”

Once installed, the system will enable local hydrogen production at HWR Hydrogen’s Invercargill refueling station, supporting the company’s dual-fuel fleet while helping establish the infrastructure required for broader hydrogen adoption across Southland and the South Island.

“We’re looking forward to installing the Plug GenEco electrolyzer equipment, which we will use at our refueling station initially to supply hydrogen for Change Fuel Technologies built dual-fuel trucks operated by HWR and other customers across the Southland region. The station will also be ready to refuel OEM-supplied hydrogen vehicles for HWR companies and the wider industry as they become available,” said Gareth Wishart, GM Technology & Innovation at HWR. “Bringing Plug equipment and capabilities to Invercargill is about proving out a model we can extend across the South Island as adoption grows.”

Plug’s work with HWR adds to a growing portfolio across Australia and New Zealand. In Australia, Plug was selected to supply a 50 MW GenEco PEM electrolyzer system for Orica’s Hunter Valley Hydrogen Hub, the largest renewable hydrogen project in Australia to reach FID, which is expected to produce approximately 4,700 metric tons of renewable hydrogen annually. In New Zealand, Plug technology is already deployed to support Hiringa Energy’s green hydrogen refueling network.

About Plug Power

Plug designs, builds, and operates a fully integrated hydrogen ecosystem spanning production, storage, delivery, and power generation, enabling the global hydrogen economy. A first mover in the industry, Plug delivers electrolyzers, fuel cells, and hydrogen production plants to customers across material handling, industrial applications, and energy markets, advancing energy resilience and industrial decarbonization.

Plug’s GenEco electrolyzers span five continents, and the Company has more than 76,000 GenDrive fuel cell systems and 280+ hydrogen-powered material handling sites deployed to date. Plug also operates its own hydrogen generation network to ensure a reliable, domestically produced supply, with production facilities currently operational in Georgia, Tennessee, and Louisiana, representing a combined capacity of approximately 40 tons per day.

With employees and state-of-the-art manufacturing facilities around the world, Plug serves global leaders including Walmart, Amazon, Home Depot, BMW, and BP.

For more information, visit www.plugpower.com.

About H.W. Richardson
H.W. Richardson Group (HWR) is one of New Zealand’s largest privately owned transport companies. Headquartered in Invercargill and family owned, HWR comprises a diverse group of businesses operating across transport, petroleum, ready-mixed concrete, contracting, quarrying and technology  services in New Zealand and Australia. Building on generations of transport experience, HWR combines long-term thinking, operational capability and innovation to support its customers. HWR Hydrogen produces hydrogen for industry and is developing local production and refuelling infrastructure to support HWR businesses and other customers. Change Fuel Technologies, also part of HWR, develops hydrogen–diesel dual-fuel systems that can be retrofitted to existing diesel engines, providing a practical pathway to reduce heavy-transport emissions.

Safe Harbor

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts, including, without limitation, statements regarding the Company’s expectations, goals, plans, outlook or prospects, positive FIDs moving projects from awards to execution stage, and other statements regarding future operating results, financial condition, performance, prospects, and opportunities, are forward-looking statements. These forward-looking statements are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of management and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. These risks and uncertainties include, among other things: Whether future HWR projects reach positive FID; Whether other Plug supplied projects in Australia and New Zealand transition to execution in 2026 or beyond; Whether Plug’s first electrolyzer deployment on South Island will help establish the infrastructure required for broader hydrogen adoption across Southland and the South Island; Orica’s Hunter Valley Hydrogen Hub expected production capacity; Whether any of the projects in the global opportunity pipeline advance to execution or positive financial investment decisions; whether Plug’s industrial solutions will help reduce carbon emissions, and help make green hydrogen more cost-effective and accessible for industrial, utility, and infrastructure customers worldwide; general market, economic, competitive, and regulatory conditions; the Company’s ability to manage costs and liquidity; risks related to the Company’s future capital requirements and liquidity needs. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Plug in general, see Plug’s public filings with the Securities and Exchange Commission (the “SEC”), including the “Risk Factors” section of Plug’s Annual Report on Form 10-K for the year ended December 31, 2025 and Plug’s subsequent Quarterly Reports on Form 10-Q, and any other subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

MEDIA CONTACT
Teal Hoyos
media@plugpower.com

Final Acceptance Certificate confirms successful completion of the one-year operational liability period

MONTREAL, Sept. 22, 2026 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis” or the “Company”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today that its subsidiary Pyro Green-Gas (“PGG”), received the Final Acceptance Certificate for a previously announced major project undertaken for Tata Steel (the “Client”), one of the world’s leading diversified steel producers. The certificate confirms successful completion of the one-year operational liability period and formally transfers responsibility for future operation of the system to the Client.

“The Final Acceptance Certificate announced today marks the culmination of years of close collaboration with Tata Steel to develop and implement a solution for one of its largest steelmaking facilities,” said Mr. P. Peter Pascali, President and CEO of PyroGenesis. “The steel industry’s off-gas processing sector has traditionally been dominated by some of the world’s largest engineering firms, making the successful completion and final acceptance of a system of this scale particularly significant for PyroGenesis. The system installed for Tata Steel covers an area equivalent to a football field and spans the height of a five-storey building. Having demonstrated our technology and engineering capabilities at this scale, we are now attracting interest from other major steelmakers. With more than 1,400 blast furnaces installed across 477 plants in 55 countries¹ and continued investment in blast-furnace steelmaking – with approximately 70% of planned new global steel projects expected to incorporate blast furnaces² – we believe there is a significant market opportunity for our advanced coke-oven gas cleaning and other steel industry technologies.”

About the Final Acceptance Certificate

As announced on July 15, 2025, PGG completed a major project for Tata Steel to develop and supply coke-oven gas purification solutions and hydrogen production processes designed to separate and recover hydrogen while removing toxic contaminants from coke oven gas. Under the terms of the agreement, PGG successfully passed all required project milestones. These milestones included (i) an Integrated Cold Test, which confirmed that all equipment and components met or exceeded the required operating and safety standards, and (ii) a Provisional Acceptance Test, which verified that the systems met agreed-upon contractual specifications.

The project completion announced in July 2025 initiated a one-year compliance and defects liability period during which system performance was monitored and PGG remained responsible for addressing any operational deficiencies. Such periods are standard for industrial projects of this scale. Generally, following the conclusion of such one-year period, a client may either extend the evaluation period or issue final acceptance, thereby assuming responsibility for future operations. Tata Steel has now issued the signed Final Acceptance Certificate, confirming completion of PGG’s work under the agreement and the transfer of responsibility for future operations of the system to Tata Steel. 

Image: PyroGenesis’ Coke Oven Gas and Hydrogen Extraction System at Tata Steel, Kalinganagar, India

About the Tata Steel Coke-Oven Gas Valorization and Hydrogen Production Project

Blast furnaces utilize coking coal, or “coke”, as part of the process to transform iron ore into steel. Coke acts as both a fuel to generate the intense heat required for smelting and as a reducing agent to remove oxygen from the iron ore. The gas released during the coke production process, known as coke-oven gas, is a toxic mix of human carcinogens comprised of approximately 54% hydrogen with the balance consisting of methane, carbon monoxide, carbon dioxide, tar, naphthalene, and other hydrocarbons which must be separated and removed before the hydrogen can be cleaned, reformed, and reused³. PyroGenesis’ subsidiary Pyro Green-Gas has decades of experience designing and installing technology solutions specifically for these situations.

As stated above, PGG supplied both coke-oven gas purification solutions and hydrogen production processes geared to extract hydrogen and other toxic gases from the blast furnace process. The gases were then separated, cleaned, and processed to render hydrogen to a 99.999% purity level. The plant has been in continuous 24 hrs./day operation at the Tata steel facility in Kalinganagar, India, where the newly reformed hydrogen produced by the system is being reused in other applications at the facility, thereby improving production efficiency and environmental outcomes. The systems installed by PGG are purifying 32,000 cubic meters of coke-oven gas per hour while extracting 620 cubic meters of ready-to-use hydrogen per hour.

About Pyro Green-Gas Inc.

Pyro Green-Gas offers technologies, equipment, and expertise in biogas upgrading and air pollution controls. Pyro Green-Gas designs and builds: (i) gas upgrading systems to convert biogas to renewable natural gas (RNG); (ii) pyrolysis-gas purification; (iii) biogas & landfill-gas flares and thermal oxidizers; and (iv) purification of coke-oven gas (a by-product in the primary steel industry arising from the conversion of coal into coke) into high purity hydrogen, which is in high demand across the industry. In addition, Pyro Green-Gas produces a line of landfill gas flares which reduce greenhouse gas emissions from landfills, and is actively involved in gas purification and separation, and reforming and synthesis of hydrocarbon gases, as well as waste gas and solid waste valorization systems.

About PyroGenesis Inc.

PyroGenesis leverages 35 years of plasma technology leadership to deliver advanced engineering solutions to energy, propulsion, destruction, process heating, emissions, and materials development challenges across heavy industry and defense. Its customers include global leaders in aluminum, aerospace, steel, iron ore, utilities, environmental services, military, and government. From its Montreal headquarters and local manufacturing facilities, PyroGenesis’ engineers, scientists, and technicians drive innovation and commercialization of energy transition and ultra-high temperature technology. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified, with ISO certification maintained since 1997. PyroGenesis’ shares trade on the TSX (PYR), OTCQX (PYRGF), and Frankfurt (8PY1) stock exchanges.

Cautionary and Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking statements. Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management’s current beliefs, expectations, estimates and projections regarding future events and operating performance. Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by PyroGenesis as of the date of this release, are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ, possibly materially, from those indicated by the forward-looking statements include, but are not limited to, the risk factors identified under “Risk Factors” in PyroGenesis’ latest annual information form, and in other periodic filings that it has made and may make in the future with the securities commissions or similar regulatory authorities, all of which are available under PyroGenesis’ profile on SEDAR+ at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect PyroGenesis. However, such risk factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. PyroGenesis undertakes no obligation to publicly update or revise any forward-looking statement, except as required by applicable securities laws. Neither the Toronto Stock Exchange, its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) nor the OTCQX Best Market accepts responsibility for the adequacy or accuracy of this press release.

For further information contact ir@pyrogenesis.com or visit http://www.pyrogenesis.com

_______________________________
¹ https://www.steeltimesint.com/news/blast-furnace-tracker-offers-first-free-global-coverage-of-blast-furnaces

² https://www.energymonitor.ai/sectors/industry/weekly-data-70-of-planned-steel-production-projects-are-dirty-blast-furnaces/

³ https://www.ncbi.nlm.nih.gov/books/NBK590934/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4304e9f9-1d83-4172-bcb3-4e890e03f339

Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients

Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa

JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.’s (“Santen”) Ryjunea® from Sydnexis, Inc. (“Sydnexis”) for a $23 million upfront payment.

Ryjunea is a once-nightly, low-dose atropine eye drop designed to slow progression of myopia (commonly known as nearsightedness) in pediatric patients. Treatment may be indicated in children aged 3-14 years with a progression rate of 0.5 D or more per year and a severity of -0.5 D to -6.0 D. The product uses a standardized 0.01% formulation of atropine with deuterated water designed to improve efficacy, comfort, and stability in the pediatric population. Santen licensed rights to Ryjunea in Europe, the Middle East, and Africa (“EMEA”) from Sydnexis in 2021. Ryjunea was approved by the European Commission in June 2025 and the UK Medicines and Healthcare products Regulatory Agency (“MHRA”) in October 2025.

“Ryjunea represents the type of differentiated asset we look to add to our expanding royalty portfolio. As the first and only approved pharmacological treatment in the European Union and the United Kingdom for slowing pediatric myopia, Ryjunea addresses a significant market need by providing a stable, clinically validated, and GMP manufactured option to manage this chronic condition. Santen has built a strong ophthalmology presence across Europe and has identified myopia as a key strategic growth area, giving us confidence in the product’s long-term commercial potential,” said Todd Davis, CEO of Ligand.

Under the terms of the agreement, Ligand will pay $23 million upfront to acquire a 100% interest in certain payments and related rights under Sydnexis’s existing license agreement with Santen. The acquired payment rights include a tiered low-double-digit to high-teens royalty on Ryjunea net sales in EMEA, as well as certain milestone payments. Sydnexis retains commercial rights to Ryjunea in the U.S. and all other non-Santen licensed territories.

Myopia is a condition in which the focal point for distant objects is in front of the retina, instead of directly on it, and results in vision loss. It has been reported that, in addition to affecting patient quality of life, the progression to “high myopia” increases the risk of severe ocular complications that can lead to permanent visual impairment or blindness. In Europe, approximately 1 in 3 children and adolescents are projected to be affected by myopia by 2050,¹ and Santen estimates 14 million patients were affected in 2025.²

McDermott Will & Schulte LLP and Cooley LLP served as legal advisors to Ligand.

About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to Ryjunea’s commercial potential; the size and growth of the market for treatments for pediatric myopia; Santen’s commercialization, market access and other activities relating to Ryjunea; future sales of Ryjunea; Ligand’s expected receipt of royalties, reimbursement approval milestones and sales milestones relating to Ryjunea and Ligand’s royalty portfolio strategy and expected revenue characteristics.

These statements are based on various assumptions and on the current expectations of Ligand’s management and are not predictions of actual performance. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, many of which are beyond Ligand’s control. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, Ligand’s reliance on Santen and other third parties for the commercialization, manufacture and sale of Ryjunea and for the payment of royalties and milestones; the possibility that Ryjunea sales may be lower than expected; the timing, availability and scope of regulatory, pricing and reimbursement approvals; competition from compounded atropine, optical treatments and existing or future pharmaceutical products; changes in market acceptance, prescribing practices or treatment guidelines; the possibility that applicable royalty rates may be reduced under the underlying license agreement; challenges to, or the expiration or invalidation of, intellectual property rights relating to Ryjunea; and the other risk factors discussed under the heading “Item 1A. Risk Factors” in the Ligand’s Annual Report on Form 10-K for the year ended December 31, 2025 (filed February 27, 2026) and Quarterly Reports on Form 10-Q for the quarter ended March 31, 2026 (filed with the SEC on May 8, 2026) and for the quarter ended June 30, 2026 (filed with the SEC on August 7, 2026). Ligand cautions against placing undue reliance on these forward-looking statements, which speak only as of the date of this press release, and undertakes no obligation to update any forward-looking statements except as required by law.

Contacts

Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761

Media:
Kellie Walsh
media@ligand.com
(914) 315-6072

---

¹ Liang J, et al. Br J Ophthalmol. 2024; bjo–2024–325427.
² Santen Pharmaceutical Co., Ltd., Santen Report 2025. https://www.santen.com/content/dam/santen/global/pdf/en/ir/document/202503/ar2025e.pdf

Company Highlights Expanding Patent Portfolio and Competitive Position While Advancing Texatron™ Testing and Preparing for Potential Uplisting to a National Securities Exchange

SOUTHLAKE, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) — American Fusion Inc. (OTCQB: AMFN) (“American Fusion” or the “Company”), a developer of advanced fusion-energy technology, today provided a comprehensive corporate update addressing the continued expansion and protection of its intellectual property portfolio, the Company’s progress as a public company, continued testing and validation of the Texatron™ platform, and its pathway toward a potential uplisting to a national securities exchange.

Protecting the Texatron™ Intellectual Property Portfolio

American Fusion reported the filing of 21 additional U.S. patent applications, bringing the Company’s intellectual property portfolio to 151 pending U.S. patent applications.

The newly filed applications continue the Company’s strategy of building multiple layers of intellectual property protection around the Texatron™ platform, including its core architecture as well as alternative configurations, materials, geometries, components, operating systems and methods that may become increasingly important as the technology advances.

131. U.S. Patent Application No. 19/802,584 — Aluminum Unitary Fusion System with Rifled Toroidal Interior Chamber and Pulsed Electrical Energy

132. U.S. Patent Application No. 19/802,608 — Quartz Clamshell Fusion Confinement Device with Rifled Toroidal Interior Chamber and Electromagnetic Foil

133. U.S. Patent Application No. 19/804,026 — Unitary Quartz Fusion Confinement Device with Rifled Toroidal Interior Chamber and Electromagnetic Foil

134. U.S. Patent Application No. 19/804,057 — Quartz Clamshell Experimental Fusion System with Electrically Generated Electromagnetic Foil Along Rifling

135. U.S. Patent Application No. 19/804,074 — Quartz Unitary Experimental Fusion System with Electrically Generated Electromagnetic Foil Along Rifling

136. U.S. Patent Application No. 19/808,626 — Quartz Clamshell Fusion Confinement System with Helium-3/Deuterium Fuel Injection and Electromagnetic Foil

137. U.S. Patent Application No. 19/805,591 — Quartz Unitary Fusion Confinement System with Helium-3/Deuterium Fuel Injection and Electromagnetic Foil

138. U.S. Patent Application No. 19/805,590 — Quartz Nuclear Fusion Reactor with Rifled Toroidal Interior Chamber and Ridge-Mounted Coil

139. U.S. Patent Application No. 19/805,593 — Nuclear Fusion Reactor with Unitary Quartz Confinement Device and Ridge-Mounted Coil

140. U.S. Patent Application No. 19/805,596 — Clamshell Quartz Fusion Confinement Device with Helium-3/Deuterium Fuel Injection and Ridge-Mounted Coil

141. U.S. Patent Application No. 19/805,599 — Unitary Quartz Fusion Confinement Device with Helium-3/Deuterium Fuel Injection and Ridge-Mounted Coil

142. U.S. Patent Application No. 19/808,629 — Quartz Clamshell Fusion System with Rifled Toroidal Chamber and Ridge-Mounted Coil

143. U.S. Patent Application No. 19/808,632 — Quartz Unitary Fusion System with Rifled Toroidal Chamber and Ridge-Mounted Coil

144. U.S. Patent Application No. 19/808,644 — Symmetrical Two-Half-Shell Quartz Fusion Confinement Device with Rifled Toroidal Chamber and Helium-3/Deuterium Fuel Injection

145. U.S. Patent Application No. 19/808,653 — Symmetrical Unitary Quartz Fusion Confinement Device with Rifled Toroidal Chamber and Helium-3/Deuterium Fuel Injection

146. U.S. Patent Application No. 19/811,469 — Symmetrical Quartz First and Second Half-Shell Apparatus with Rifled Toroidal Chamber and Equal Helium-3/Deuterium Fuel Injection

147. U.S. Patent Application No. 19/811,472 — Geometrically Symmetrical Unitary Quartz Confinement Apparatus with Approximately Equal Helium-3/Deuterium Fuel Injection

148. U.S. Patent Application No. 19/811,476 — Symmetrical Quartz First and Second Hemisphere Fusion System Forming a Rifled Toroidal Interior Chamber

149. U.S. Patent Application No. 19/813,120 — Symmetrical Unitary Quartz Fusion Housing Forming a Rifled Toroidal Interior Chamber

150. U.S. Patent Application No. 19/813,122 — Asymmetrical Unequal Two-Shell Quartz Fusion System Forming a Rifled Toroidal Interior Chamber

151. U.S. Patent Application No. 19/813,124 — Asymmetrical Unitary Quartz Fusion Containment Device Forming a Rifled Toroidal Interior Chamber

American Fusion believes the importance of this strategy extends considerably beyond the number of patent applications filed. The commercial fusion industry is attracting substantial investment, but even some of the industry’s most heavily funded participants are now publicly discussing timelines extending into 2029 and 2030 for full operation of planned commercial fusion power facilities. American Fusion believes the Texatron™ platform may offer a materially shorter pathway to commercialization, although significant testing, validation and engineering work remains and there can be no assurance that the Company will achieve its targeted timeline.

Management believes this potential time-to-market advantage substantially increases the importance of protecting the Company’s intellectual property. As the Texatron™ advances, American Fusion is attracting increasing attention from within the fusion industry, prospective commercial counterparties, investors and others seeking greater information regarding the technology and its underlying engineering. The Company believes that protecting inventions, designs, configurations, components and methods before providing detailed technical disclosure is essential to preserving its potential competitive advantage.

American Fusion intends to continue providing shareholders with meaningful and timely information regarding the Company’s progress. At the same time, management believes transparency must be balanced against the obligation to protect proprietary information that could have substantial commercial value. The Company does not intend to disclose technical information simply to satisfy outside interest when doing so could compromise intellectual property or provide competitors with insight into the Texatron™ platform before appropriate protections are in place.

Brent Nelson, Executive Chairman of American Fusion, commented: “The fusion industry is moving toward commercialization, but the timelines being discussed by other major participants increasingly extend toward the end of this decade. We believe the Texatron™ may provide us with an opportunity to move considerably faster. If we are right, protecting the technology becomes even more important. We are not going to sacrifice a potential competitive advantage simply to disclose engineering details before the underlying intellectual property has been appropriately protected.”

Nelson continued: “Our intellectual property strategy is designed to protect not merely a single fusion device, but a family of Texatron™ Fusion Engines™ and the technologies that may support multiple sizes, configurations, applications and future generations of the platform. We believe that intellectual property may ultimately represent one of American Fusion’s most important long-term corporate assets.”

Patent applications remain subject to examination by the U.S. Patent and Trademark Office, and there can be no assurance that any particular application will result in an issued patent or that any patent ultimately issued will provide commercially meaningful protection.

Texatron™ Testing and Development Infrastructure

American Fusion continues to pursue additional testing of the Texatron™️ platform at a local university facility while advancing plans for a dedicated, Company-controlled testing facility.

The Company believes establishing its own testing infrastructure is an important next step in the Texatron™️ development program. A dedicated facility would give American Fusion greater control over testing schedules, equipment configuration, diagnostic instrumentation and engineering workflows, and would allow the Company to conduct testing without many of the scheduling and operational constraints inherent in performing advanced research within third-party facilities.

American Fusion has identified a site for the facility and has negotiated the principal terms and purchase price. The Company expects to enter escrow on the property through its affiliate. Completion of the transaction remains subject to customary closing conditions, and there can be no assurance that it will close on the anticipated terms or at all. The Company will file additional details with the Securities and Exchange Commission on a Current Report on Form 8-K, as required.

The dedicated facility is intended to complement, rather than replace, the work already performed through the Company’s university and third-party relationships. American Fusion expects outside scientific, engineering and institutional resources to remain important components of its broader validation program.

“As the Texatron™️ program advances, we need the ability to test when the engineering requires it, rather than only when a third-party facility is available,” said Brent Nelson. “Securing our own testing facility will give our scientific and engineering teams considerably greater control over the pace and sequencing of the program, while allowing us to configure the equipment and diagnostics specifically around the Texatron™️.”

The Texatron™️ Fusion Engine™️ continues to undergo testing and engineering validation.

Pathway Toward a National Exchange Uplisting

American Fusion is advancing preparations for a potential uplisting of its common stock from the OTCQB to a national securities exchange.

The Company has been evaluating the Texas Stock Exchange (“TXSE”) as its preferred potential venue, while also evaluating the New York Stock Exchange (“NYSE”) and Nasdaq as alternative venues. Based on its evaluation to date, American Fusion believes TXSE represents a particularly compelling option given the Company’s Texas domicile, its Texas headquarters and the substantial engineering and development work it conducts within the state. The Company has not made a final venue determination and intends to select the exchange it believes will provide the strongest long-term platform for American Fusion and its shareholders.

Based on its review to date, the Company believes it currently satisfies TXSE’s initial listing criteria other than the minimum bid-price requirement. American Fusion believes it may be eligible to list under TXSE’s $200 million market-capitalization standard based on its current valuation. With respect to the minimum bid-price requirement, the Company will evaluate, based on the trading price of its common stock at the time of the proposed uplisting, whether a reverse stock split would be necessary to meet that requirement.

TXSE’s rules provide for a confidential pre-application eligibility review before a prospective issuer submits an original listing application. Upon successful completion of that review, TXSE may issue a clearance letter permitting an eligible company to proceed with a formal listing application. American Fusion, together with its securities and capital markets advisors, is preparing to position the Company for that process.

The Company believes much of the infrastructure required for a national-exchange listing was put in place through the work completed during 2026, including audited financial statements, SEC reporting status, current periodic reporting, improved quotation infrastructure, OTCQB qualification and the continued development of its board and corporate-governance structure. American Fusion continues to evaluate the remaining requirements and available qualification pathways, as well as potential capital-markets transactions that could accompany an uplisting.

The Company has also received several financing term sheets from various funds contemplating potential capital in connection with a national-exchange uplisting, along with additional funding intended to accelerate commercialization of the Texatron™️ platform. American Fusion is evaluating these proposals alongside other potential financing alternatives. No definitive financing agreement has been executed, and there can be no assurance that any proposed financing will be completed or, if completed, on what terms.

American Fusion has been invited to visit the New York Stock Exchange, where Chief Executive Officer Brent Nelson and members of the management team will participate in an interview with New to The Street, filmed on the floor of the exchange on Monday, September 28, 2026, to provide an update on the Company. New to the Street is a national TV broadcasts on Bloomberg TV and FOX Business. While in New York, management will also meet with several banks and institutional investors that have expressed interest in the Company.

“OTCQB was never intended to be the final destination for American Fusion,” said Brent Nelson. “It was an important step in building the reporting, governance and market infrastructure required for where we intend to take the Company. We are now working through the requirements and available pathways for a potential national-exchange uplisting.”

Nelson continued, “TXSE is particularly interesting to us. American Fusion is a Texas company developing advanced energy technology in Texas, the energy capital of the United States, and we believe there is a natural alignment with a national securities exchange headquartered here. We are also evaluating the NYSE and Nasdaq, and will ultimately pursue the venue and structure that we believe best positions American Fusion for its next stage of development and commercialization.”

Any potential national-exchange uplisting remains subject to the satisfaction of all applicable listing requirements, completion of the applicable exchange review process, market conditions and approval by the selected exchange. The Company’s belief regarding its eligibility is based on its own assessment and has not been confirmed by TXSE. There can be no assurance that American Fusion will qualify for or complete an uplisting to TXSE, NYSE, Nasdaq or any other national securities exchange, or that any reverse stock split, if effected, would enable the Company to meet or maintain applicable listing requirements.

About American Fusion Inc.

American Fusion Inc. (OTCQB: AMFN) is an advanced energy platform company focused on the development and commercialization of next-generation fusion energy technologies. The Company is advancing the Texatron™ Fusion Engine™ aneutronic fusion platform, designed for modular, infrastructure-grade deployment across industrial, commercial, defense and grid-constrained applications.

The Company’s development strategy emphasizes system-level engineering, disciplined intellectual-property protection and scalable architectures intended to support long-term commercial operation, while maintaining a focus on capital discipline and transparent corporate governance.

For more information about American Fusion and its Texatron™ platform, please visit: americanfusionenergy.com

For an overview of American Fusion, please click here: American Fusion Overview

Forward-Looking Statements

This press release contains forward-looking statements regarding future events and the future performance of American Fusion Inc., including statements regarding American Fusion’s intellectual property portfolio and pending and future patent applications; the development, testing, validation, anticipated performance, scalability and potential applications of the Texatron™ Fusion Engine™; commercialization, manufacturing, financing, strategic partnerships, regulatory approvals and customer opportunities; the Company’s evaluation of a potential listing on the Texas Stock Exchange; satisfaction of applicable listing standards and completion of any related corporate or capital-markets actions; and other future business operations. Words such as “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and similar expressions are intended to identify forward-looking statements.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Patent applications are subject to examination and there can be no assurance that any application will result in an issued or commercially valuable patent. The developed Texatron™ Fusion Engine™ is undergoing testing and continued engineering validation and has not demonstrated sustained net electricity generation from a commercial system. There can be no assurance that the Company will achieve its scientific, engineering, regulatory, financing, manufacturing or commercialization objectives, satisfy the applicable initial listing standards of TXSE, receive approval to list its common stock on TXSE or complete any potential listing. This press release does not constitute an offer to sell or solicitation of an offer to purchase securities. Readers should not place undue reliance on forward-looking statements, and American Fusion undertakes no obligation to update them except as required by law.

Corporate Communications

833-872-2636 ext. 730
ir@americanfusionenergy.com
info@americanfusionenergy.com
americanfusionenergy.com

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) — Premier American Uranium Inc. (“PUR”, the “Company” or “Premier American Uranium”) (TSXV: PUR) (OTCQB: PAUIF) announces that Mr. Tim Rotolo has resigned as Chairman and a director of the Company, effective September 21, 2026. Michael Harrison, a current director of PUR, has been appointed Chairman of the Board.

Mr. Rotolo has played an important leadership role in PUR since its formation in late 2023, initially serving as the Company’s Chief Executive Officer before transitioning to Chairman in March 2024. During his tenure, PUR significantly expanded its U.S. uranium portfolio through the acquisitions of American Future Fuel Corporation and Nuclear Fuels Inc. and recently announced a strategic transaction with DISA Uranium Corporation. Mr. Rotolo indicated that his decision follows the achievement of an important milestone in the strategy Sachem Cove helped establish for PUR: building a meaningful U.S. uranium platform and attracting a strategic partner capable of supporting its next phase of growth. The Company’s recently announced transaction with DISA Uranium represents the realization of that strategy.

Colin Healey, Chief Executive Officer of PUR, commented, “On behalf of the Board and management team, I would like to thank Tim for his leadership and significant contributions to PUR. From serving as PUR’s first CEO to guiding the Company as Chairman, Tim has been instrumental in building the business and establishing the foundation we have today. We are pleased that Sachem Cove will remain PUR’s largest shareholder and continue to support the Company as we enter our next phase of growth.”

Tim Rotolo, commented, “When Sachem Cove backed PUR, our thesis was that a disciplined consolidator with the right team could build a meaningful U.S. uranium platform and attract the type of strategic partner capable of accelerating its development. The recent transaction with DISA Uranium represents the realization of that thesis and positions PUR exceptionally well for its next chapter. With that strategic relationship now in place, I believe this is the right time for me to step away from the Board and focus on Sachem Cove’s other commitments. I am proud of what the team has accomplished since PUR’s formation and confident in its ability to execute the strategy from here. Sachem Cove remains PUR’s largest shareholder, and we look forward to continuing to support the Company from the shareholder side.”

Mr. Harrison has served as a director of PUR since its formation and brings more than 30 years of mining, capital markets and transaction experience. As Managing Partner of Sprott Streaming and Royalty, he has extensive experience financing and advising mining companies, including uranium developers. His uranium-sector experience includes the merger of Denison Mines Inc. and International Uranium Corporation, the initial public offering of Virginia Uranium Inc., and prior directorships with Uranium Royalty Corp. and Macusani Yellowcake Inc.

Michael Harrison, Chairman, commented, “I am pleased to assume the role of Chairman at an important point in PUR’s development. The Company has assembled a strong portfolio across several leading U.S. uranium districts, and the strategic relationship with DISA Uranium provides additional financial and technical support as PUR advances its core assets. I look forward to working with the Board and management team to build on this foundation. I would also like to thank Tim for his leadership and the important role he has played in establishing PUR.”

About Premier American Uranium Inc.

Premier American Uranium is focused on consolidating, exploring, and developing uranium projects across the United States to strengthen domestic energy security and advance the transition to clean energy. The Company’s extensive land position spans five of the nation’s top uranium districts, with active work programs underway in New Mexico’s Grants Mineral Belt and Wyoming’s Great Divide and Powder River Basins.

Backed by strategic partners including Sachem Cove Partners, IsoEnergy Ltd., Mega Uranium Ltd., and other leading institutional investors, PUR is advancing a portfolio supported by defined resources and high-priority exploration and development targets. Led by a distinguished team with deep expertise in uranium exploration, development, permitting, operations, and uranium-focused M&A, the Company is well positioned as a key player in advancing the U.S. uranium sector.

For More Information, Please Contact:

Premier American Uranium Inc.
Colin Healey, CEO

info@premierur.com
Toll-Free: 1-833-223-4673
Twitter: @PremierAUranium
www.premierur.com

Neither TSX Venture Exchange nor its Regulations Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information includes, but is not limited to, statements with respect to, planned activities including the closing of the transaction with DISA Uranium and the benefits thereof; and other activities, events or developments that are expected, anticipated or may occur in the future. Generally, but not always, forward-looking information and statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or the negative connotation thereof or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof.

Forward-looking information and statements are based on our current expectations, beliefs, assumptions, estimates and forecasts about PUR’s business and the industry and markets in which it operates. Such forward-information and statements are based on numerous assumptions, including among others, that the transaction with DISA Uranium will be completed and that the benefits of the strategic transaction with DISA Uranium will be achieved, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms, that third party contractors, equipment and supplies and governmental and other approvals required to conduct the Company’s planned exploration activities will be available on reasonable terms and in a timely manner. Although the assumptions made by PUR in providing forward-looking information or making forward-looking statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate.

Forward-looking information and statements also involve known and unknown risks and uncertainties and other factors, which may cause actual results, performances and achievements of Premier American Uranium to differ materially from any projections of results, performances and achievements of Premier American Uranium expressed or implied by such forward-looking information or statements, including, among others: that the transaction with DISA Uranium may not be completed and that the benefits thereof may not be realized, the limited operating history of the Company, negative operating cash flow and dependence on third party financing, uncertainty of additional financing, delays or failure to obtain required permits and regulatory approvals, changes in mineral resources, no known mineral reserves, aboriginal title and consultation issues, reliance on key management and other personnel; potential downturns in economic conditions; availability of third party contractors; availability of equipment and supplies; failure of equipment to operate as anticipated; accidents, effects of weather and other natural phenomena and other risks associated with the mineral exploration industry; changes in laws and regulation, competition, and uninsurable risks and the risk factors with respect to Premier American Uranium set out in PUR’s annual information form for the year ended December 31, 2024 and the other documents of PUR filed with the Canadian securities regulators and available under PUR’s profile on SEDAR+ at www.sedarplus.ca.

Although PUR has attempted to identify important factors that could cause actual actions, events or results to differ materially from those contained in the forward-looking information or implied by forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements or information. PUR undertakes no obligation to update or reissue forward-looking information as a result of new information or events except as required by applicable securities law.

Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain 

Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated neurological disease

SUNRISE-FA 2 pivotal study continues enrollment and remains the company’s top priority development program; topline data on track for 2H 2027

Disciplined capital allocation supports these strategic initiatives while maintaining cash runway into 2028

Company to host webcast today at 8:00 AM ET

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire Mantle Therapeutics Inc. and three new research collaborations supporting cerebellar-targeted development opportunities for frataxin gene therapy. Together, these transactions will simultaneously expand Lexeo’s vision and capabilities beyond gene therapy, deepen the company’s focus on the multisystem burden of FA, and add multiple therapeutic approaches designed to increase or restore frataxin in the brain. These transactions are being pursued within Lexeo’s existing balance sheet capacity, with cash runway guidance unchanged into 2028 and future investment decisions guided by predefined milestones to identify and prioritize the most compelling central nervous system (CNS) opportunities.

“Our objective is to build the best-in-class therapeutic platform for the treatment of Friedreich ataxia,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “LX2006 remains our highest priority as the best-in-class treatment for FA cardiomyopathy, and the addition of Mantle’s pipeline, combined with new research collaborations will broaden our technology platform with multiple complementary CNS-targeted therapeutic strategies designed to restore frataxin in the brain and further improve outcomes for individuals living with FA. Together, these initiatives will strengthen our leadership position in the disease category while supporting disciplined portfolio advancement and capital allocation.”

Acquisition of Mantle Therapeutics Will Establish Lexeo’s Multimodal Friedreich Ataxia Platform

On September 16^th, 2026, Lexeo entered into an agreement to acquire Mantle Therapeutics Inc. (“Mantle”), a private clinical stage company focused on developing multiple therapies for the treatment of FA. The acquisition will deepen Lexeo’s focus on FA and strengthen its capabilities in addressing the neurologic aspects of disease.

The acquired portfolio will include:

• LX3010 (MTL-104): a clinical stage, oral combination therapy designed to increase frataxin expression while addressing mitochondrial function and oxidative stress through complementary mechanisms (HDAC inhibition and NRf2). Early clinical data includes an approximately 6-point improvement in mFARS scores at 16 weeks and a mean nine-fold increase in frataxin protein levels from baseline in muscle biopsies across 11 FA patients.
• LX3030 (MTL-707): a pre-clinical stage oral, tissue-penetrant true small molecule (sub-500Da) designed to increase production of endogenous frataxin in the central nervous system. LX3030 is a third-generation benzamide HDAC inhibitor that builds on published clinical work demonstrating oral benzamide HDACs increase frataxin in FA patients by epigenetic modulation and acetylation of chromatin. Preclinical studies of LX3030 have demonstrated robust increases in frataxin, supporting continued evaluation of LX3030 as a differentiated oral therapy.
• LX3050 (MTL-501): a pre-clinical stage recombinant human frataxin fused to a proprietary anti-TfR1 Fab, intended to directly replace the deficient frataxin protein and utilize a TfR1-targeting brain shuttle designed to cross the blood-brain barrier and increase delivery of frataxin to the brain. In vitro studies have demonstrated dose-responsive improvements in measures of mitochondrial function, providing early support for the program’s proposed mechanism.
• LX3070 (MTL-801): a discovery stage ASO Fab conjugate program designed to stabilize FXN mRNA and thereby increase translation of endogenous frataxin protein. The program combines an RNA-targeted mechanism conjugated to a proprietary anti-TfR1 Fab. In vitro studies have demonstrated dose-responsive increases in frataxin.

Under the terms of the agreement, Lexeo will pay Mantle shareholders $8.3 million in upfront consideration, consisting of a combination of cash and equity. The agreement also provides for up to $13.0 million in success-based milestone payments, payable in a combination of cash and equity upon the achievement of future clinical and regulatory milestones, bringing the total potential consideration to $21.3 million. Subject to customary closing conditions, the transaction is expected to close in the third quarter of 2026.

Following closing, Lexeo will continue its evaluation of the acquired programs against predefined scientific, clinical, strategic and financial criteria and will prioritize investment in the opportunities demonstrating the strongest potential for clinical patient impact, regulatory success and shareholder value creation. The Company’s cash runway guidance into 2028 includes plans to advance one of the acquired programs into clinical development. The Company expects to provide a program prioritization update in early 2027 and submit an IND for its next FA development candidate in 2027.

Together with LX2006, the expanded portfolio provides Lexeo with the technology to evaluate multiple biologic theses for the treatment of FA in the brain. These complementary therapies will be evaluated both as standalone treatments and in concert with LX2006, and all future clinical trials are expected to include a treatment arm for patients previously treated with LX2006.
  
Strategic Collaborations Supporting Sequential Dosing of CNS Targeted Frataxin Gene Therapy

Lexeo has established three collaborations to evaluate cerebellar-targeted sequential dosing of frataxin gene therapy, all designed to be complementary to systemically administered LX2006.

• Weill Cornell Medicine Cerebellar-Targeted Sequential Dosing Research: Lexeo entered into a Sponsored Research Agreement with Weill Cornell Medicine to evaluate intra-cisternal administration of LX2006 following systemic dosing in large animal models. The collaboration is intended to further the understanding and translation of cerebellar-targeted sequential dosing, and to evaluate dosing parameters and immune-suppression strategies that may support repeat administration.
• Vivet Therapeutics IgG-Degrading VTX-PID Enzyme Option Agreement: Lexeo entered into an option agreement with Vivet Therapeutics providing the opportunity to secure an exclusive license to VTX-PID, an IgG-degrading enzyme intended to support immune-suppression strategies that may expand treatable population with immunization against AAV and facilitate repeat administration of LX2006.
• Apertura Gene Therapy Novel CNS Capsid (CapX) Option Agreement: Lexeo entered into an option agreement with Apertura Gene Therapy providing the opportunity to secure a license to a novel, intravenously administered, blood-brain barrier-crossing capsid that is expected to enable a less invasive route of administration to the CNS following initial systemic administration of LX2006.

Similarly, Lexeo intends to evaluate the outcomes of these research collaborations against predefined scientific, clinical and financial criteria and prioritize investment in opportunities with the greatest potential to advance into clinical development and provide FA patients with a sequential CNS-dosing option to complement prior systemic administration of LX2006.

Expanded Vision to Reflect Strategic Focus

Lexeo is introducing an expanded vision reflecting the company’s focus on the treatment of genetic diseases with high unmet need in both the cardiovascular and neurological space. The refreshed positioning aligns with Lexeo’s growing Friedreich ataxia platform and expanded portfolio across multiple modalities outside of gene therapy.

Continued Advancement of LX2006

LX2006 continues to advance enrollment in the SUNRISE-FA 2 pivotal study, which remains Lexeo’s highest operational and capital-allocation priority. The program remains on track to provide a topline data readout in the second half of 2027. The Company believes LX2006 has the potential to become the first disease-modifying therapy specifically targeting Friedreich ataxia cardiomyopathy.

Corporate Webcast Details
Lexeo Therapeutics will host a webcast at 8:00 AM ET today, September 22, 2026. Analysts and investors can participate by accessing the webcast live on the Events & Presentations page in the Investors section of Lexeo’s website, www.lexeotx.com. The webcast will be archived on the company’s website following the call.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, the anticipated benefits of its current product candidates, the timing for receipt and announcement of data from its clinical trials, the timing and likelihood of potential regulatory developments, trial design changes and approval, expectations regarding the time period over which Lexeo’s capital resources will be sufficient to fund its anticipated operations and estimates regarding Lexeo’s financial condition, the expected closing of the proposed acquisition of Mantle Therapeutics Inc. and the satisfaction of the conditions thereto, the anticipated benefits of the proposed acquisition and the acquired programs, the timing and outcome of Lexeo’s evaluation of the acquired programs and research collaborations against predefined criteria, the expected timing of a program prioritization update, the expected submission of an IND for Lexeo’s next Friedreich ataxia development candidate, and the potential achievement of future clinical and regulatory milestones. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 12, 2026, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Media Response:
Media@lexeotx.com

Investor Response:
Ashley Kaplowitz
akaplowitz@lexeotx.com

BROOMFIELD, Colo., Sept. 22, 2026 (GLOBE NEWSWIRE) — Gogo Special Missions, the military/government division of Gogo (NASDAQ: GOGO), and Insitu, a Boeing company, announced today the successful completion of testing and integration of a new, modified high-speed satellite connectivity solution, tailored specifically for Group 3 Uncrewed Aerial Systems (UAS). The leading Group 3 UAS OEM and the leading Global UAS connectivity supplier have partnered to optimize the Gogo Galileo HDX antenna for installation on Insitu’s Integrator UAS.

“The Integrator UAS offers theater-level range and capacity for multiple customer payloads. Adding an ITAR-free, high-speed SATCOM option is an essential capability for our global customers—extending command and control and allowing seamless backhaul of sensor data with minimal latency. We are pleased to partner with Gogo, which will deliver a turnkey solution that includes UAS equipment, satellite services, and 24/7 support,” says John Kelly, Vice President of Growth of Insitu.

“The collaboration with Insitu is particularly exciting, as it gives us the opportunity to modify our proven HDX solution, specifically to address the fast-growing Group 3 UAS market,” explains Ben Massey, Senior Vice-President & General Manager of Gogo Special Missions. “With our antenna system further optimized for size and weight, Insitu customers will now be able to access high-speed, global internet over Eutelsat’s OneWeb LEO satellite constellation, with a single line replaceable unit (LRU) configuration.”

The two companies successfully completed integration and testing of the customized Gogo Galileo HDX on the Integrator this month, alongside the FLARES Vertical Take-off and Landing kit. This new capability requires minimal deck space, can launch in high seas and gusty winds, and requires zero aircraft modifications.

Photo caption: Gogo Special Missions and Insitu have successfully completed testing and integration of a new, modified high-speed satellite connectivity solution tailored specifically for Group 3 Uncrewed Aerial Systems (UAS).

About Gogo

Gogo has been the trusted connectivity infrastructure partner for military and government operations and business aviation for three decades. Rather than promoting a single network or technology, Gogo Special Missions has a network-neutral approach, helping military and government customers navigate an increasingly complex communications landscape by combining deep market knowledge and global aviation expertise to identify, integrate and support the connectivity solution best suited to each mission and operational requirement.

Providing access to a complete connectivity ecosystem through a single trusted partner, Gogo Special Missions offers onboard hardware, software, air-to-ground and multi-orbit, multi-band satellite connectivity, service plans, and 24/7/365 multilingual customer support. The company’s interoperable solutions securely connect crewed and uncrewed aircraft across the operational theatre, enabling seamless communications in any mission environment. Dedicated to customer success, Gogo Special Missions delivers the flexibility, resilience and choice customers need while ensuring predictable pricing and future-proof technology.

From ISR and command-and-control missions to executive transport, humanitarian operations and emergency response, Gogo delivers secure, reliable, mission-critical connectivity that enables customers to execute every mission with confidence.

About Insitu

Boeing subsidiary Insitu is a pioneer in the design, development, production, and operation of high-performance, cost-effective, resilient, VTOL-capable UAS and AI-enabled software solutions. Insitu’s technologies have helped the armed forces of 35 nations make quicker, more informed decisions to bring warfighters home safely.

With offices in the US, Australia, the UK, and the UAE, Insitu has manufactured and fielded more than 3,500 UAS and provides operations and support networks in every hemisphere of the globe. Learn more at Insitu.com.

Media contacts

Caroline Phaneuf – Arena Group         
Caroline@arenagroupassociates.com                                
+1 514 778 5092                                

Stacey Giglio         
sgiglio@gogoair.com                 
+1 321 361 6101

Cautionary Note Regarding Forward-Looking Statements

Certain disclosures in this press release and related comments by our management include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding our business outlook, industry, business strategy, plans, goals and expectations concerning our market position, international expansion, future technologies, future operations, margins, profitability, future efficiencies, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release. Forward-looking statements are based on our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to have been correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, the following: our ability to continue to generate revenue from the provision of our connectivity and other service offerings; our development and fixed-price contracts; our reliance on our key OEMs and dealers for equipment sales; our dependence on single-source, third party satellite network providers; the impact of competition; our ability to maintain high-quality customer support; our reliance on third parties for equipment components and services; our participation in U.S. government contracts; our participation in non-U.S. government contracts; the finite useful life of satellites; the impact of global supply chain and logistics issues, tariffs and inflationary trends; the continued expansion of our business outside of the United States; foreign currency risk; our ability to recruit, train and retain highly skilled employees, and the loss of any key personnel; the impact of pandemics or other outbreaks of contagious diseases, and the measures implemented to combat them; the impact of adverse economic conditions; our ability to fully utilize portions of our deferred tax assets; the impact of attention to climate change, conservation measures and other sustainability-related matters; our ability to evaluate or pursue strategic opportunities; our ability to integrate Satcom Direct’s business, and the potential failure to realize or delay in realizing all of the anticipated benefits of the acquisition; the changes in executive management that occurred as part of the Satcom Direct acquisition; our ability to develop and deploy Gogo 5G, Gogo Galileo or other next generation technologies; our ability to maintain our rights to use our licensed 4Mhz of ATG spectrum in the United States and obtain rights to additional spectrum if needed; the impact of service interruptions or delays, cyberattacks, technology failures, equipment damage or system disruptions or failures; the impact of assertions by third parties of infringement, misappropriation or other violations; our ability to innovate and provide products and services; our ability to protect our intellectual property rights; risks associated with the use of artificial intelligence in our products and services; the impact of our use of open-source software; the impact of equipment failure or material defects or errors in our software; our ability to comply with applicable foreign ownership limitations; the impact of government regulation of communication networks, and the internet; the ongoing partial government shutdown; our possession and use of personal information; risks associated with participation in the FCC Reimbursement Program; our ability to comply with anti-bribery, anti-corruption and anti-money laundering laws; the extent of expenses, liabilities or business disruptions resulting from litigation; the impact of global climate change and legal, regulatory or market responses to it; the impact of the distribution of income among various jurisdictions in which we operate as well as changes in tax law or regulation on our U.S. and non-U.S. tax liabilities; the impact of changes in laws and regulations on U.S. government contractors; the impact of our substantial indebtedness; our ability to obtain additional financing to refinance or repay our existing indebtedness the impact of restrictions and limitations in the agreements and instruments governing our debt; the impact of an increase in interest rates; the impact of a substantial portion of our indebtedness being secured by substantially all of our assets; the impact of a substantial change in rating assigned by a rating agency; the volatility of our stock price; our ability to fully utilize our tax losses; the dilutive impact of future stock issuances; the impact of our stockholder concentration; our ability to fulfill the obligations of being  a public company; the impact of an identified material weakness in our internal controls; the impact of certain provisions of our charter, bylaws, and Delaware law; and other factors listed under the caption “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025 as filed with the Securities and Exchange Commission (“SEC”) on February 27, 2026 and in our subsequent quarterly reports on Form 10-Q as filed with the SEC.

Any one of these factors or a combination of these factors could materially affect our financial condition or future results of operations and could influence whether any forward-looking statements contained in this report ultimately prove to be accurate. Our forward-looking statements are not guarantees of future performance, and you should not place undue reliance on them. All forward-looking statements speak only as of the date made and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0bce0916-2beb-4543-9890-41b6f3fc909c